Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Sales and Divestitures: 2017-2025

Historic Gains from Sales and Divestitures for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $608,833.

  • Aclaris Therapeutics' Gains from Sales and Divestitures rose 12.16% to $608,833 in Q3 2025 from the same period last year, while for Sep 2025 it was $608,833, marking a year-over-year increase of 12.16%. This contributed to the annual value of $1.5 million for FY2024, which is 97.69% up from last year.
  • Aclaris Therapeutics' Gains from Sales and Divestitures amounted to $608,833 in Q3 2025, which was up 2.32% from $595,035 recorded in Q2 2025.
  • Aclaris Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $1.5 million during Q4 2024, with a 5-year trough of $377,371 in Q1 2021.
  • For the 3-year period, Aclaris Therapeutics' Gains from Sales and Divestitures averaged around $660,424, with its median value being $595,035 (2025).
  • As far as peak fluctuations go, Aclaris Therapeutics' Gains from Sales and Divestitures plummeted by 60.89% in 2022, and later skyrocketed by 97.69% in 2024.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Gains from Sales and Divestitures stood at $1.3 million in 2021, then plummeted by 60.21% to $533,212 in 2022, then skyrocketed by 39.77% to $745,279 in 2023, then skyrocketed by 97.69% to $1.5 million in 2024, then increased by 12.16% to $608,833 in 2025.
  • Its Gains from Sales and Divestitures stands at $608,833 for Q3 2025, versus $595,035 for Q2 2025 and $525,753 for Q1 2025.